Medicare has completed its second round of price negotiations for 15 top-selling prescription drugs and posted maximum fair prices, per an Inflation Reduction Act provision. The announced net prices, to go into effect in 2027, are on average 44% lower than they were last year. getty

Without much fanfare and just before Thanksgiving weekend commenced, the Trump administration released the prices Medicare will pay for 15 top-selling prescription drugs. Negotiations led by the Centers for Medicare and Medicaid Services resulted in 44% lower net prices than health plans participating in Medicare’s outpatient pharmacy benefit program (Part D) were paying in 2024. Additionally, this figure is twice as large as the 22% achieved during the first round of negotiations.

The 15 selected drugs

See Full Page